{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:22Z","timestamp":1785886762127,"version":"3.56.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020437","name":"Beijing Association for Science and Technology","doi-asserted-by":"publisher","award":["BYESS2022170"],"award-info":[{"award-number":["BYESS2022170"]}],"id":[{"id":"10.13039\/501100020437","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>The clinical manifestations of neuromyelitis optica spectrum disorders (NMOSD) overlap with those of other central nervous system (CNS) disorders, making differential diagnosis based on symptoms alone difficult. This study aimed to identify distinguishing indicators of aquaporin-4 (AQP4) IgG-negative NMOSD and assess their diagnostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed four groups: 85 patients with AQP4-IgG-negative NMOSD, 192 with AQP4-IgG-positive NMOSD, 547 with other nervous system autoimmune disorders (e.g., multiple sclerosis, Guillain-Barr\u00e9 syndrome, and viral and autoimmune encephalitis), and 269 healthy controls matched for sex, age, and BMI.A diagnostic model was established using clinical, biochemical, and cerebrospinal fluid (CSF) variables. The dataset was divided into training and internal validation cohorts, and model performance was further assessed through external validation using an independently collected dataset obtained during the same study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 1,093 participants. The AQP4-IgG-negative NMOSD group showed: higher diplopia incidence (35.29% vs. 17.19% in positive NMOSD, 17.18% in controls; P&amp;lt;0.001); lower limb sensory abnormalities (76.47% vs. 89.58%, P = 0.0056) and urinary dysfunction (36.47% vs. 57.29%, P = 0.0017) than positive cases; predominant brainstem involvement (50.59% vs. 31.77% in positive, 28.70% in controls; P&amp;lt;0.001); moderate spinal cord involvement (70.59% vs. 88.02% in positive, 38.57% in controls; P&amp;lt;0.001); and altered thyroxine, apolipoprotein A1, eosinophils, and basophils. After false discovery rate correction (q&amp;lt;0.1), diplopia, brainstem involvement, spinal cord involvement, serum albumin, and CSF albumin remained significant. A combined model incorporating twelve predictors (Ocular symptoms, Gastrointestinal symptoms, Water swallowing and choking difficulties, Cerebral lobes, Centrum semiovale, Brainstem, Cerebral ganglia, Spinal cord, APOA1, Ca, Toxoplasma gondii IgM Antibody, CSF IgG) achieved an AUC of 0.936in the training cohort and 0.929 in external validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>AQP4-IgG-negative NMOSD shows distinct clinical, imaging, and laboratory profiles compared to other nervous system autoimmune disorders. A multi-indicator diagnostic approach offers higher accuracy than single-marker diagnostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1637613","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:34Z","timestamp":1768372774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Wencan","family":"Jiang","sequence":"first","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxu","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelin","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowei","family":"Ding","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Huang","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical University, Youanmen","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical University, Youanmen","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Engineering Research Center of Immunological Reagents Clinical Research","place":["Beijing, China"]},{"name":"NMPA Key Laboratory for Quality Control of In Vitro Diagnostic","place":["Beijing, China"]},{"name":"Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06853-2","article-title":"Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data","volume":"44","author":"Jiang","year":"2023","journal-title":"Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01792-1","article-title":"Frequency of diencephalic syndrome in NMOSD","volume":"122","author":"Etemadifar","year":"2022","journal-title":"Acta Neurol Belg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01206-x","article-title":"Monoclonal antibody therapies beyond complement for NMOSD and MOGAD","volume":"19","author":"Redenbaugh","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124","article-title":"International delphi consensus on the management of AQP4-igG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxad053","article-title":"Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody","volume":"213","author":"Chu","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":". Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1337339","article-title":"Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation","volume":"18","author":"Tieck","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/brainsci12070885","article-title":"NMOSD-diagnostic dilemmas leading towards final diagnosis","volume":"12","author":"Szewczyk","year":"2022","journal-title":"Brain Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jped.2019.07.006","article-title":"Viral encephalitis: a practical review on diagnostic approach and treatment","author":"Costa","year":"2020","journal-title":"J Pediatr (Rio J)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2974","article-title":"Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder","volume":"80","author":"Fu","year":"2023","journal-title":"JAMA Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09716-4","article-title":"The clinical profile of NMOSD in Australia and New Zealand","volume":"267","author":"Bukhari","year":"2020","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1011579","article-title":"Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD","volume":"13","author":"Fadda","year":"2022","journal-title":"Front Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"105559","DOI":"10.1016\/j.msard.2024.105559","article-title":"Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives","volume":"85","author":"Lorefice","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1039\/C8AN01046C","article-title":"Lipid metabolism in inflammation-related diseases","volume":"143","author":"Zhang","year":"2018","journal-title":"Analyst"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/cancers11081097","article-title":"Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer","volume":"11","author":"Georgila","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-023-01166-y","article-title":"Serum LDL promotes microglial activation and exacerbates demyelinating injury in neuromyelitis optica spectrum disorder","volume":"40","author":"Chen","year":"2024","journal-title":"Neurosci Bull"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06876-9","article-title":"Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register","volume":"44","author":"Mosconi","year":"2023","journal-title":"Neurol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neures.2017.11.001","article-title":"Dissociation of blood-brain barrier disruption and disease manifestation in an aquaporin-4-deficient mouse model of amyotrophic lateral sclerosis","volume":"133","author":"Watanabe-Matsumoto","year":"2018","journal-title":"Neurosci Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02101","article-title":"Intestinal barrier breakdown and mucosal microbiota disturbance in neuromyelitis optical spectrum disorders","volume":"11","author":"Cui","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12974-023-02997-2","article-title":"Bruton\u2019s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder","volume":"20","author":"Liu","year":"2023","journal-title":"J Neuroinflamm"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1038\/s41598-021-94423-x","article-title":"Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study","volume":"11","author":"Karrenbauer","year":"2021","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1637613\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:35Z","timestamp":1768372775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1637613\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1637613"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1637613","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1637613"}}